论文部分内容阅读
目的比较CYP11B2在正常与实验性肝纤维化大鼠肝组织中的表达,评价安体舒通的抗纤维化作用。方法取雄性wistar大鼠160只,随机平均分为4组。模型组:CCLA油0.25mL/100mg皮下注射,每周三次;安舒体通组:CCLA油0.25ml/100mg皮下注射,每周三次;安体舒通20mgkg/d灌胃,1次/曰;马洛替脂组:CCLA油0.25ml/100mg皮下注射。每周三次:马洛替脂50ml/kg/d灌胃,1次/日;对照组:橄榄油0.25/ml/100mg皮下注射,每周次。于2、4、6、8、1O周末在光镜下动态观察组织学改变,图象分析仪测量胶原面积。RT-PCR和原位杂交检测纤维化及正常肝组织CYP11B2mRN的表达。结果 RT-PCR显示CYP11B2mRN在纤维化肝组织中表达上调。原位杂交显示CYP11B2mRNA表达定位于储脂细胞胞浆,在纤维化形成时表达增细。在肝纤维化形成的早中期阶段(6周以前),用安体舒通治疗能使肝纤维化分级和胶原面积减少。结论 CYP11R2mRNA在纤维化肝脏的储脂细胞中表达增强。安体舒通对早中期肝纤维化具有一定的治疗作用。
Objective To compare the expression of CYP11B2 in liver tissue of normal and experimental liver fibrosis rats and evaluate the anti-fibrosis effect of spironolactone. Methods 160 male wistar rats were randomly divided into 4 groups randomly. The model group: CCLA oil 0.25mL / 100mg subcutaneous injection, three times a week; Anshu Tong Tong group: CCLA oil 0.25ml / 100mg subcutaneous injection three times a week; spironolactone 20mgkg / d gavage, 1 / Malotiose group: CCLA oil 0.25ml / 100mg subcutaneous injection. Three times a week: Mallow replacement 50ml / kg / d gavage, 1 / day; control group: olive oil 0.25 / ml / 100mg subcutaneous injection, weekly. At 2, 4, 6, 8 and 1O weekend we observed histological changes under light microscope, and image analyzer measured collagen area. The expression of CYP11B2mRN in fibrosis and normal liver tissue was detected by RT-PCR and in situ hybridization. Results RT-PCR showed that CYP11B2mRN was up-regulated in fibrotic liver tissue. In situ hybridization showed that the expression of CYP11B2 mRNA localized in the cytoplasm of fat-storing cells and increased in the formation of fibrosis. In the early to mid-stage of liver fibrosis (6 weeks ago), spironolactone treatment reduced liver fibrosis grade and collagen area. Conclusion The expression of CYP11R2 mRNA is enhanced in lipid-storing cells of fibrotic liver. Spironolactone on the early and middle liver fibrosis has a certain therapeutic effect.